|
Dr. Bianchi is Executive Vice President, Commercial at Millennium Pharmaceuticals Inc., which markets VELCADE® (bortezomib) for injection, a therapy for blood cancers. Prior to joining Millennium in 2006, Dr. Bianchi served as the head of the U.S. oncology business unit of Sanofi-Aventis, with responsibility for brands such as Eloxatin® and Taxotere®. From 2001 through 2004, Dr. Bianchi served as Vice President of the Internal Medicine and Central Nervous System Business Unit of Sanofi. In 2000, Dr. Bianchi served as President of Europe and Senior Vice President of Global Marketing and Business Development for SangStat Medical Corporation, a biotechnology firm later acquired by Genzyme. Between 1990 and 2000, Dr. Bianchi held several positions of increasing responsibility at Rhone-Poulenc Rorer in the U.S., culminating in his appointment to Vice President and Head of Global Marketing. During that period he led many of the domestic and global commercial efforts for its antithrombotic, Lovenox®.
Dr. Bianchi earned an M.D. from the University of Reims-Champagne in France and an M.B.A. from the Wharton School at the University of Pennsylvania. He is also a graduate of Ecole Des Hautes Etudes Commerciales (EDHEC Graduate School of Management) in France. | 